Sutro Biopharma, Inc. STRO NASDAQ

Sutro Biopharma, Inc. (STRO) reported total assets of $173.83M and total liabilities of $306.28M for fiscal year 2025, resulting in total equity of $-132.45M.

The company held $141.43M in cash and short-term investments. Total debt stood at $15.67M, with net debt of $-42.46M. The Debt-to-Equity (D/E) ratio was -0.12 (conservative).

Current ratio is 2.01, indicating strong short-term liquidity. Interest coverage is -2.7x (weak).

Criteria supported by this page:

• HEALTH (50/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (58/100) — Total assets $173.83M and equity $-132.45M support the company's competitive scale
• VALUE (63/100) — Debt-to-Equity -0.12 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 42/100 with 1/7 criteria passed.

PCVX

Vaxcyte, Inc.

$60.45

-3.68%

MRUS

Merus N.V.

$90.00

+0.00%

CNTA

Centessa Pharmaceuticals plc

$39.61

+0.05%

OPT

Opthea Limited

$3.41

+1.49%

IDYA

IDEAYA Biosciences, Inc.

$32.18

-0.53%

NAMSW

NewAmsterdam Pharma Company N.V.

$24.04

+2.71%

SNDX

Syndax Pharmaceuticals, Inc.

$24.33

-0.41%

MLYS

Mineralys Therapeutics, Inc.

$30.42

+11.35%